C2i Genomics

Company Overview

Snapshot

Founded in August 2019 by Asaf Zviran, Boris Oklander, and Ezra Sofer, C2i Genomics operates with 11–50 employees. The company raised $113.2 million across 3 funding rounds from 9 investors, with Casdin Capital participating in multiple rounds. In January 2024, C2i Genomics was acquired by Veracyte.

Business overview

C2i Genomics provides a SaaS solution for ultra-sensitive whole-genome cancer detection and tumor burden monitoring. Its cloud-based platform leverages existing genome sequencers globally, applying scientific breakthroughs, genomic and clinical databases, sophisticated signal processing, and artificial intelligence. This technology enables high-precision personalized medicine, aims to reduce cancer treatment costs, and accelerates drug development by recognizing patient-specific cancer patterns through whole genome sequencing and a proprietary AI-based tumor enrichment method. The company operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Digital Medical Diagnostics.

Strategic signal

In January 2024, C2i Genomics was acquired by Veracyte for up to $95 million, including $70 million in Veracyte shares at closing and up to an additional $25 million based on future performance milestones. This acquisition signals strong market validation for C2i Genomics' whole-genome tumor sequencing technology, as Veracyte plans to integrate it to develop new minimal residual disease (MRD) tests, particularly for muscle-invasive bladder cancer and other focused indications. This move indicates a significant growth opportunity for the technology within the cancer diagnostics market and demonstrates a strategic expansion for Veracyte.

Company Intelligence Q&A

What was the most significant recent corporate development for C2i Genomics?

In January 2024, C2i Genomics was acquired by Veracyte for up to $95 million. The deal included $70 million in Veracyte shares at closing, with an additional $25 million contingent on achieving future performance milestones over two years.

What was the nature of the collaboration between C2i Genomics and AstraZeneca?

In January 2023, AstraZeneca evaluated C2i Genomics' whole-genome minimal residual disease assay and cancer-monitoring platform for use in clinical research and drug development. This collaboration aimed to improve treatment monitoring and clinical trial recruitment, building on a previous partnership through AstraZeneca's BeyondBio Innovation Hub program.

What strategic partnership did C2i Genomics form in India?

In June 2022, C2i Genomics partnered with Karkinos Healthcare to develop the first whole-genome sequencing (WGS) MRD test in India. This collaboration aimed to enhance diagnostic capabilities and expand MRD monitoring within the Karkinos health system using C2i Genomics' AI-powered whole-genome analysis.

Which investors participated in C2i Genomics' Series B funding round?

In April 2021, C2i Genomics raised a Series B round with participation from investors including.

What was the purpose of C2i Genomics' acquisition of QNA Dx?

In March 2021, C2i Genomics acquired CLIA-certified sequencing lab QNA Dx to accelerate the commercialization of its MRDetect cancer monitoring platform. This acquisition was intended to scale cancer sample processing capacity and facilitate the offering of centralized lab services.